我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

辛伐他汀联合依那普利干预对急性冠脉综合征患者 血清C反应蛋白和白介素-6的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第2期
页码:
137-139
栏目:
临床研究
出版日期:
2005-03-05

文章信息/Info

Title:
Influence of intervention with simvastatin and enalapril on the levels of CRP and IL6 in patients with acute coronary syndrome
作者:
罗明; 俞文萍; 王宏保
同济大学附属同济医院 心内科, 上海 200065
Author(s):
LUO Ming;  YU Wenping;  WANG Hongbao
Department of Cardiology, Tongji Hospital, Tongji University, shanghai 200065,China
关键词:
急性冠脉综合征; 辛伐他汀; 依那普利; C反应蛋白质; 白介素-6
Keywords:
acute coronary syndrome;  simvastatin;  enalapril;  Creactive protein;  interleukin6
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的 探讨急性冠脉综合征(ACS)患者C反应蛋白(CRP)和白介素6(IL6)的变化及辛伐他汀、依那普利对其的影响。方法 对急性冠脉综合征患者83例和对照组130例检测血清CRP和IL6及对83例急性冠脉综合征患者进行联合辛伐他汀和依那普利的干预，探讨ACS患者CRP和IL6的变化及辛伐他汀和依那普利对其影响。结果 ① 治疗前ACS组的CRP和IL6分别为16.08±1.22 mg/L和30.21±8.34 μg/L，与对照组比较P<0.01，② ACS组经4周辛伐他汀联合依那普利治疗后CRP和IL6分别为8.33±1.21 mg/L和16.11±4.67 μg/L，与治疗前比较P<0.01。结论 ACS患者CRP和IL6水平均有明显升高，存在明显的炎症反应。辛伐他汀联合依那普利治疗能有效抑制此类炎症反应。
Abstract:
AIM To observe the influence of intervention with simvastatin and enalapril on the levels of Creactive protein(CRP) and interleukin6(IL6) in patients with acute coronary syndrome(ACS). METHODS The levels of serum CRP, IL6 were detected respectively in 83 cases of ACS ,130 of matched controls. 83 cases of ACS received simvastatin and enalapril therapy to observe the influence of intervention with simvastatin and enalapril on the levels of CRP and IL6 in patients with ACS. RESULTS ①The levels of CRP, IL6 were significantly higher in patients with ACS than in controls (16.08±1.22 mg/L vs 4.13±0.76 mg/L,P<0.01;30.21±8.34 μg/L vs 11.25±4.54 μg/L,P<0.01) respectively. ②After treatment with simvastatin and enalapril for 4 weeks, the levels of CRP,IL6 in 83 patients with ACS decreased significantly(16.08±1.22 mg/L vs 8.33±1.21 mg/L,P<0.01, 30.21±8.34 μg/L vs 16.11±4.67 g/L,P<0.01) . CONCLUSION The levels of CRP, IL6 increased significantly in patients with ACS.Inflammation may play an important role in the ACS. Treatment with simvastatin and enalapril can inhibit the reaction of inflammation in patients with ACS and play a role in antiatherosclerosis.

参考文献/References

［1］ Maseri A. Inflammation, atherosclerosis,and ischemic events-exploring the hidden side of the moon［J］. N Engl J Med,1977,336:1014-1016.

［2］Ross R. Atherosclerosis-an inflammatory disease［J］. N Engl J Med,1999,340(2):115-126.

［3］ Gaspardone A,Crea F,Versaci F,et al. Predictive value of Creactive protein after successful coronaryartery stenting in patients with stable angina［J］. Am J Cardiol,1998,82:515-518.

［4］ Yudkin JS,Kumari M,Humphries SE,et al. Inflammation,obesity,stress and coronary heart disease:is interleukin6 the link? ［J］. Atherosclerosis,2000,148(2):209-214.

［5］ 高智耀，雷北军，李亚军，等. 辛伐他汀在不稳定型心绞痛患者早期应用的疗效［J］.心脏杂志，2004，16（2）：140-143.

［6］李崇剑，徐耕，傅国胜，等. 不同类型冠心病患者血清C反应蛋白与白细胞介素6的比较［J］.临床心血管病杂志,2003,19(10):585-586.

［7］ Oltrona L,Ardissino D,Merlini PA,et al. Creactive protein elevation and early outcome in patients with unstable angina pectoris［J］. Am J Cardiol,1997,80:1002-1004.

备注/Memo

备注/Memo:
收稿日期：2004-07-07.
更新日期/Last Update: 2010-01-05